Redmile Group’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-4,205,206
Closed -$102M – 80
2023
Q1
$102M Sell
4,205,206
-296,905
-7% -$6.5M 4.44% 3
2022
Q4
$96.4M Buy
4,502,111
+1,102,211
+32% +$23.5M 3.94% 6
2022
Q3
$61M Buy
3,399,900
+1,881,000
+124% +$24.7M 2.37% 13
2022
Q2
$14.6M Buy
1,518,900
+33,100
+2% +$415K 0.56% 44
2022
Q1
$25M Sell
1,485,800
-14,200
-0.9% -$210K 0.78% 36
2021
Q4
$25.1M Buy
+1,500,000
New +$24.6M 0.57% 42
2016
Q4
– Sell
-505,154
Closed -$23.3M – 60
2016
Q3
$23.3M Buy
+505,154
New +$28.5M 1.85% 20
2014
Q2
– Sell
-19,374
Closed -$692K – 59
2014
Q1
$692K Sell
19,374
-297,147
-94% -$10M 0.08% 49
2013
Q4
$10.2M Buy
+316,521
New +$9.39M 1.26% 35

Other funds holding ISEE

Redmile Group's ISEE Position: Q2 2023 in Review

Redmile Group sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q2 2023, closing a stake of 4,205,206 shares — an estimated $102M sold.

Redmile Group first reported a position in ISEE in Q4 2013 and held it in 9 quarters. The position peaked at $102M in Q1 2023. 255 funds tracked by Wall St. Rank hold ISEE as of Q2 2023.

  • Redmile Group reported no remaining IVERIC bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Redmile Group sold 4,205,206 IVERIC bio, Inc. Common Stock shares in Q2 2023, an estimated $102M.
  • Redmile Group first reported a position in IVERIC bio, Inc. Common Stock in Q4 2013 and held it in 9 quarters.
  • Redmile Group's IVERIC bio, Inc. Common Stock position peaked at $102M in Q1 2023.
  • 255 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q2 2023.

Based on Redmile Group's 13F filing for Q2 2023, filed 14 Aug 2023.